取材予定演題リスト｜GI cancer-net 海外学会速報レポート 2019年1月サンフランシスコ

取材予定演題リスト

※本リストに掲載の演題は、発表前の限られた情報をもとに取材候補として選んだものです。
諸事情により、予告なく取材・掲載を取り止める場合がありますので、あらかじめご了承ください。

Oral

Abstract #2

Late-Breaking Abstract
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.

Takashi Kojima, et al.

Abstract #62

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).

Yelena Janjigian, et al.

Abstract #187

Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E?mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial.

Zev Wainberg, et al.

Abstract #188

Integrative molecular profiling and response to chemotherapy on the COMPASS trial.

Grainne O'Kane, et al.

Abstract #189

Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).

Michiaki Unno, et al.

Abstract #480

A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.

Carl Schimanski, et al.

Rapid

Abstract #5

Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study.

Hirva Mamdani, et al.

Abstract #7

Parallel-group controlled trial of esophagectomy versus chemoradiotherapy in patients with clinical stage I esophageal carcinoma (JCOG0502).

Ken Kato, et al.

Abstract #484

A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer: The ACTS-CC 02 trial.

Takao Takahashi, et al.